LAKE FOREST, Calif.,
June 17, 2015 /PRNewswire/
-- Cryoport, Inc. (OTCBB: CYRX) ("Company"), the leading
provider of advanced cryogenic logistics solutions for the life
sciences industry, serving markets including immunotherapies, stem
cells, cell lines, clinical research organizations, vaccine
manufacturers, animal health, and reproductive medicine, today
announced that the Company is the preferred cryogenic logistics
provider to CaRE Arthritis ("CaRE").
Cryoport's comprehensive cryogenic logistics solutions will
support CaRE Arthritis and their efforts in the development of
personalized care options for arthritis. Cryoport's validated
solutions provide integrity for temperature sensitive shipments
supporting patient access for CaRE Arthritis research and
development efforts. Cryoport offers a global network for
greater safety and speed of the delivery.
CaRE Arthritis, based in Alberta,
Canada, is an academic research organization that supports
research and education for arthritis to patients and medical
professionals, with an emphasis on the growing field of
personalized medicine. The people of CaRE specialize in the
development and application of biomarkers and medical imaging to
further the advancement of the understanding of the disease.
Biomarkers can play a critical role in identifying the severity of
arthritic patients as well as their response to treatment.
Dr. Walter Maksymowych, Chief
Medical Officer of CaRE Arthritis, stated, "The development and
application of new imaging and biomarker technologies is an
essential step to bringing the concept of personalized medicine to
reality in the day-to-day management of arthritis. With the
support of Cryoport's cold chain logistics, we are working
tirelessly to better understand and efficiently treat the
disease."
Jerrell Shelton, Chief Executive
Officer of Cryoport, commented, "We look forward to working with
CaRE Arthritis to help them advance their research efforts.
We offer comprehensive as well as best-in-class cryogenic solutions
to an industry that needs reliability in order to accelerate
forward. Cryoport is being recognized as a critical partner
to the research community from a wide range of
organizations."
About Cryoport, Inc.
Cryoport is the premier provider of cryogenic logistics
solutions to the life sciences industry through its purpose-built
proprietary packaging, information technology and specialized cold
chain logistics expertise. We provide leading edge logistics
solutions for biologic materials such as immunotherapies, stem
cells, CAR-T cells, and reproductive cells for clients worldwide
including points-of-care, CRO's, central laboratories,
pharmaceutical companies, contract manufacturers, and university
researchers. Our packaging is built around our proprietary Cryoport
Express® liquid nitrogen dry vapor shippers, which are validated to
maintain a constant -150°C temperature for a 10 day dynamic
shipment duration. Our information technology centers around our
Cryoportal™ Logistics Management Platform, which facilitates
management of the entire shipment process. Cryoport is the
preferred cryogenic logistics solutions partner to the world's
largest shipping companies controlling more than 85% of the world's
air shipments. For more information, visit www.cryoport.com.
To download Cryoport's investor relations app, which offers
access to SEC documents, press releases, videos, audiocasts and
more, please click to download from your iPhone and iPad
or Android mobile device.
Forward Looking Statements
Statements in this news release which are not purely
historical, including statements regarding Cryoport, Inc.'s
intentions, hopes, beliefs, expectations, representations,
projections, plans or predictions of the future are forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. It is important to note that the company's
actual results could differ materially from those in any such
forward-looking statements. Factors that could cause actual results
to differ materially include, but are not limited to, risks and
uncertainties associated with the effect of changing economic
conditions, trends in the products markets, variations in the
company's cash flow, market acceptance risks, and technical
development risks. The company's business could be affected by a
number of other factors, including the risk factors listed from
time to time in the company's SEC reports including, but not
limited to, the annual report on Form 10-K for the year ended
March 31, 2015. The company cautions
investors not to place undue reliance on the forward-looking
statements contained in this press release. Cryoport, Inc.
disclaims any obligation, and does not undertake to update or
revise any forward-looking statements in this press
release.
Logo -
http://photos.prnewswire.com/prnh/20140401/NY95107LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/cryoport-selected-for-logistics-support-of-care-arthritis-personalized-medicine-efforts-300100617.html
SOURCE Cryoport, Inc.